Personalized Medicine for Depression: Can We Match Patients with Treatments?

Overview

Journal Am J Psychiatry

Specialty Psychiatry

Date 2010 Sep 17

PMID 20843873

Citations 127

Authors

Gregory E Simon

Roy H Perlis

Affiliations

Soon will be listed here.

Abstract

Objective: Response to specific depression treatments varies widely among individuals. Understanding and predicting that variation could have great benefits for people living with depression.

Method: The authors describe a conceptual model for identifying and evaluating evidence relevant to personalizing treatment for depression. They review evidence related to three specific treatment decisions: choice between antidepressant medication and psychotherapy, selection of a specific antidepressant medication, and selection of a specific psychotherapy. They then discuss potential explanations for negative findings as well as implications for research and clinical practice.

Results: Many previous studies have examined general predictors of outcome, but few have examined true moderators (predictors of differential response to alternative treatments). The limited evidence indicates that some specific clinical characteristics may inform the choice between antidepressant medication and psychotherapy and the choice of specific antidepressant medication. Research to date does not identify any biologic or genetic predictors of sufficient clinical utility to inform the choice between medication and psychotherapy, the selection of specific medication, or the selection of a specific psychotherapy.

Conclusions: While individuals vary widely in response to specific depression treatments, the variability remains largely unpredictable. Future research should focus on identifying true moderator effects and should consider how response to treatments varies across episodes. At this time, our inability to match patients with treatments implies that systematic follow-up assessment and adjustment of treatment are more important than initial treatment selection.

Citing Articles

Neural signatures of emotional biases predict clinical outcomes in difficult-to-treat depression.

Fennema D, Barker G, ODaly O, Godlewska B, Carr E, Goldsmith K Res Dir Depress. 2025; 1:e21.

PMID: 40028885 PMC: 11869767. DOI: 10.1017/dep.2024.6.

Prediction of individual treatment allocation between electroconvulsive therapy or ketamine using the Personalized Advantage Index.

Wade B, Pindale R, Luccarelli J, Li S, Meisner R, Seiner S NPJ Digit Med. 2025; 8(1):127.

PMID: 40016503 PMC: 11868618. DOI: 10.1038/s41746-025-01523-3.

The Use of MRI and TMS in Treatment-Resistant Depression: Advances in Pediatric Applications.

Ha T, Jakimier K, OSullivan S Brain Sci. 2025; 15(2).

PMID: 40002526 PMC: 11853665. DOI: 10.3390/brainsci15020194.

Recurrent negative autobiographical memories and mental health.

Kredlow M, Fitzgerald H, Carpenter J, Taghian N, Otto M, Hofmann S J Mood Anxiety Disord. 2025; 8.

PMID: 39803366 PMC: 11721819. DOI: 10.1016/j.xjmad.2024.100074.

Validity and reliability of the Depression Information Needs Scale among the Iranian general population.

Jafari A, Naddafi F, Nejatian M, Charoghchian Khorasani E, Tehrani H Front Psychiatry. 2024; 15:1388447.

PMID: 39290305 PMC: 11406337. DOI: 10.3389/fpsyt.2024.1388447.

References

Ransohoff D, Feinstein A . Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med. 1978; 299(17):926-30. DOI: 10.1056/NEJM197810262991705. View

Perlis R, Ganz D, Avorn J, Schneeweiss S, Glynn R, Smoller J . Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005; 25(5):427-34. DOI: 10.1097/01.jcp.0000177553.59455.24. View

. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000; 157(4 Suppl):1-45. View

Thase M, Buysse D, Frank E, Cherry C, Cornes C, Mallinger A . Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles. Am J Psychiatry. 1997; 154(4):502-9. DOI: 10.1176/ajp.154.4.502. View

Kraemer H, Frank E, Kupfer D . Moderators of treatment outcomes: clinical, research, and policy importance. JAMA. 2006; 296(10):1286-9. DOI: 10.1001/jama.296.10.1286. View

Cobbin D, Williams L, Williams W . Urinary MHPG levels and tricyclic antidepressant drug selection. A preliminary communication on improved drug selection in clinical practice. Arch Gen Psychiatry. 1979; 36(10):1111-5. DOI: 10.1001/archpsyc.1979.01780100081007. View

Cipriani A, Furukawa T, Salanti G, Geddes J, Higgins J, Churchill R . Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373(9665):746-58. DOI: 10.1016/S0140-6736(09)60046-5. View

Bishop J, Moline J, Ellingrod V, Schultz S, Clayton A . Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology. 2006; 31(10):2281-8. DOI: 10.1038/sj.npp.1301090. View

Fournier J, DeRubeis R, Hollon S, Dimidjian S, Amsterdam J, Shelton R . Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010; 303(1):47-53. PMC: 3712503. DOI: 10.1001/jama.2009.1943. View

10.

Zetin M, Hoepner C, Bjornson L . Rational antidepressant selection: applying evidence-based medicine to complex real-world patients. Psychopharmacol Bull. 2006; 39(1):38-104. View

11.

Simon G, Ludman E, Tutty S, Operskalski B, Von Korff M . Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: a randomized controlled trial. JAMA. 2004; 292(8):935-42. DOI: 10.1001/jama.292.8.935. View

12.

Parikh S, Lam R . Clinical guidelines for the treatment of depressive disorders, I. Definitions, prevalence, and health burden. Can J Psychiatry. 2001; 46 Suppl 1:13S-20S. View

13.

Tadic A, Muller M, Rujescu D, Kohnen R, Stassen H, Dahmen N . The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet. 2006; 144B(3):325-31. DOI: 10.1002/ajmg.b.30462. View

14.

Papakostas G, Fava M . Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues Clin Neurosci. 2009; 10(4):439-51. PMC: 3181892. View

15.

Schelleman H, Stricker B, de Boer A, Kroon A, Verschuren M, Van Duijn C . Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs. 2004; 64(16):1801-16. DOI: 10.2165/00003495-200464160-00006. View

16.

Durham L, Webb S, Milos P, Clary C, Seymour A . The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl). 2003; 174(4):525-9. DOI: 10.1007/s00213-003-1562-3. View

17.

Perlis R, Fijal B, Adams D, Sutton V, Trivedi M, Houston J . Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry. 2008; 65(9):785-91. DOI: 10.1016/j.biopsych.2008.10.002. View

18.

Gilbody S, Whitty P, Grimshaw J, Thomas R . Educational and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA. 2003; 289(23):3145-51. DOI: 10.1001/jama.289.23.3145. View

19.

Maddux R, Riso L, Klein D, Markowitz J, Rothbaum B, Arnow B . Select comorbid personality disorders and the treatment of chronic depression with nefazodone, targeted psychotherapy, or their combination. J Affect Disord. 2009; 117(3):174-9. DOI: 10.1016/j.jad.2009.01.010. View

20.

Thase M, Friedman E, Biggs M, Wisniewski S, Trivedi M, Luther J . Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007; 164(5):739-52. DOI: 10.1176/ajp.2007.164.5.739. View